Janux Therapeutics Inc (JANX) AI Stock Analysis

• Market Cap: $1.39B
• Dividend Yield: N/A
• Average Volume (3M): 788.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.00
• Revenue Growth: 28.12%
• EPS Growth: -11.01%
• Country: US
• Employees: 91
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 59,175,156
• 10 Day Avg. Volume: 801,390
• 30 Day Avg. Volume: 788,248
• PEG Ratio: 3.25
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -32.49
• Enterprise Value/Market Cap: 1.05
• Enterprise Value/Revenue: 1.18K
• Enterprise Value/Gross Profit: -2.66K
• Enterprise Value/Ebitda: -79.59
• 1Y Price Target: $81.00
• Price Target Upside: 243.80% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 51 Neutral
• Price Target: $26.00 ▲(10.36%Upside)

The overall stock score of Janux Therapeutics Inc is primarily influenced by its financial performance, characterized by strong revenue growth but offset by profitability challenges and reliance on financing. Technical analysis shows positive short-term momentum, although longer-term trends are weak. Valuation remains a concern due to negative earnings. The lack of dividend yield also limits immediate shareholder returns.

Positive Factors

Clinical Program Development

Janux's expansion into 1L and 2L mCRPC markets represents a significant opportunity with a total market potential of approximately $10 billion in the U.S. alone.

Financial Position

With a strong cash position of approximately $1 billion, Janux is well funded to achieve clinical proof of concept for the three new programs.

Preclinical and Novel Programs

Janux raises the curtain on three preclinical programs, showcasing their ability to expand the company’s pipeline beyond ongoing clinical programs.

Negative Factors

Regulatory and Development Risks

The combinations bring added development and regulatory risk and complexity.

Safety Data Concerns

Janux has not provided detailed safety data in the latest update, leaving some uncertainty.

Janux Therapeutics Inc Business Overview & Revenue Model

Company Description

Janux Therapeutics Inc (JANX) is a biotechnology company focused on developing next-generation immunotherapies for cancer treatment. Utilizing its proprietary Tumor Activated T Cell Engager (TRACTr) platform, Janux aims to create therapies that enhance the immune system's ability to recognize and eliminate cancer cells while minimizing impact on healthy tissue.

How the Company Makes Money

Janux Therapeutics Inc generates revenue primarily through strategic collaborations and partnerships with larger pharmaceutical companies. These partnerships often include upfront payments, milestone payments, and potential royalties on sales if the developed therapies receive regulatory approval and market success. Additionally, Janux may engage in licensing agreements for its proprietary technology, contributing to its revenue streams. The company invests heavily in research and development to advance its pipeline of immunotherapy candidates, which, upon successful clinical trials and regulatory approval, could lead to commercialization and direct sales revenue.

Janux Therapeutics Inc Financial Statement Overview

Summary

Janux Therapeutics Inc demonstrates strong revenue growth and a robust balance sheet with minimal debt. Despite these strengths, the company faces challenges with profitability and cash generation from operations, as indicated by negative net income and operating cash flows. The company remains reliant on financing to support its cash needs.

Income Statement

Janux Therapeutics Inc has shown a significant increase in revenue from $8.08 million in 2023 to $10.59 million in 2024, representing a growth rate of approximately 30.4%. However, the company continues to operate at a net loss with a net profit margin of -651.6% for 2024. The gross profit margin remains high at 100%, but negative EBIT and EBITDA margins indicate operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The company maintains a strong equity base with a stockholders' equity of $1.02 billion, indicating solid foundational support. The debt-to-equity ratio is low at 0.02, suggesting minimal leverage which reduces financial risk. However, the equity ratio at 96.3% shows heavy reliance on equity financing. Return on equity is negative, reflecting ongoing losses.

Cash Flow

Operating cash flow is negative, showing the company is not generating cash from its core operations. Nevertheless, there was an improvement in free cash flow from -$52.43 million in 2023 to -$44.17 million in 2024, reflecting a positive growth rate in free cash flow. The financing cash flow remains strong due to significant cash inflows from financing activities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.59M	8.08M	8.61M	3.64M	0.00
Gross Profit	8.53M	6.13M	7.77M	3.52M	-13.00K
EBITDA	-98.85M	-71.02M	-66.25M	-32.82M	-4.83M
Net Income	-68.99M	-58.29M	-54.15M	-32.56M	-5.25M
Balance Sheet
Total Assets	1.06B	380.41M	364.01M	379.82M	16.22M
Cash, Cash Equivalents and Short-Term Investments	1.03B	344.03M	327.02M	374.96M	7.81M
Total Debt	23.02M	24.54M	25.30M	194.00K	0.00
Total Liabilities	38.73M	36.06M	43.27M	13.50M	30.86M
Stockholders Equity	1.02B	344.35M	320.74M	366.33M	-14.64M
Cash Flow
Free Cash Flow	-44.17M	-52.42M	-49.37M	-18.46M	-4.37M
Operating Cash Flow	-43.81M	-50.58M	-42.92M	-16.98M	-4.37M
Investing Cash Flow	-258.02M	-41.19M	58.27M	-340.96M	0.00
Financing Cash Flow	713.24M	59.55M	500.00K	386.52M	11.52M

Janux Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 23.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JANX, the sentiment is Negative. The current price of 23.56 is below the 20-day moving average (MA) of 25.51, below the 50-day MA of 24.79, and below the 200-day MA of 37.27, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 38.55 is Neutral, neither overbought nor oversold. The STOCH value of 8.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JANX.

Janux Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KYMR	60 Neutral	$3.01B	―	-32.17%	―	-25.85%	-23.89%
AGIO	59 Neutral	$2.03B	3.17	64.05%	―	30.57%	―
RXRX	54 Neutral	$2.45B	―	-86.10%	―	29.32%	-11.00%
Sector *	51 Neutral	$7.37B	0.33	-68.94%	2.37%	16.27%	0.42%
JANX	51 Neutral	$1.39B	―	-9.32%	―	28.12%	-11.01%
BEAM	50 Neutral	$1.89B	―	-38.04%	―	-82.38%	-164.76%
IRON	43 Neutral	$2.04B	―	-23.34%	―	―	-14.19%

Janux Therapeutics Inc Corporate Events

Janux Therapeutics Holds 2025 Annual Stockholders Meeting

On June 11, 2025, Janux Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, with 56,239,312 shares represented. During the meeting, stockholders elected three Class I directors to serve until the 2028 Annual Meeting, ratified Ernst & Young LLP as the independent accounting firm for 2025, approved executive compensation, and decided on the frequency of future advisory votes on executive compensation.

The most recent analyst rating on (JANX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Janux Therapeutics Inc stock, see the JANX Stock Forecast page.